MicroRNA expression profiles of esophageal cancer

Feber, Andrew; Xi, Liqiang; Luketich, James D.; Pennathur, Arjun; Landreneau, Rodney J.; Wu, Maoxin; Swanson, Scott J.; Godfrey, Tony E.; Litle, Virginia R.

doi:10.1016/j.jtcvs.2007.08.055

Cited by 350 publications

(303 citation statements)

References 38 publications

(27 reference statements)

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…MiR-21 has been confirmed to be overexpressed in many malignancies such as gastric cancer (Chan et al, 2008), pancreatic cancer (Roldo et al, 2006), hepatocellular cancer (Meng et al, 2007), colon cancer (Slaby et al, 2007), breast cancer (Iorio et al, 2005), prostate cancer (Volinia et al, 2006), brain tumor (Chan et al, 2005), cholangiocarcinoma (Meng et al, 2006), lung cancer (Markou et al, 2008), esophageal cancer (Feber et al, 2008), head and neck cancer (Tran et al, 2007), and ovarian cancer (Iorio et al, 2007). In addition, clinical significance of serum miR-21 expression in human cancers has been reported in recent investigations.…”

Section: Discussionmentioning

confidence: 99%

Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer

Xu¹,

Xi²,

Ge³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Recent investigations have confirmed up-regulation of serum miR-21 and its diagnostic and prognostic value in several human malignancies. In this study, we examined serum miR-21 levels in epithelial ovarian cancer (EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showed significantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serum miR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival. These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be used as a therapeutic target for the treatment of EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer

Xu¹,

Xi²,

Ge³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…28 The expression of miR-205 is highly specific for squamous epithelium, 29 and it has been shown to be downregulated in both esophageal adenocarcinoma and ESCC. 30 miR-205 has also been found to function as an oncosuppressor in breast cancer and to improve responsiveness to tyrosine kinase inhibitor therapies. 31 Furthermore, miR-224, miR-27a and miR-200a have also been associated with hepatocellular carcinoma, ESCC and ovarian cancer, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…The global miRNA expression analyses (hierarchical clustering and principal component analysis) showed that the expression profiles of the miRNAs differed between the cisplatin-sensitive and -resistant cell lines (Figure 2), and expression levels of 45 miRNAs were changed by more than fourfold in cisplatin-sensitive cell lines as compared with cisplatin-resistant cell lines (Supplementary Table 1). Subsequently, the expression levels of the 10 miRNAs that were selected according to the miRNA microarray data and literature search [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] were validated by quantitative reverse transcription-PCR. This confirmed that miR-141, miR-21, miR-19b, miR-200a, miR-19a, miR-27a, miR-20a and miR-20b were expressed at significantly higher levels in the cisplatinresistant lines, and miR-205 and miR-224 at significantly lower levels than in the cisplatin-sensitive cell lines (Po0.05) (Table 1).…”

Section: Cisplatin-sensitive and -Resistant Human Escc Cell Linesmentioning

confidence: 99%

MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous non-coding RNAs that function as negative regulators of gene expression. Alterations in miRNA expression have been shown to affect tumor growth and response to chemotherapy. In this study, we explored the possible role of miRNAs in cisplatin resistance in esophageal squamous cell carcinoma (ESCC). First we assessed the sensitivity of nine human ESCC cell lines (KYSE series) to cisplatin using an in vitro cell viability assay, and then we compared the miRNA profiles of the cisplatin-sensitive and -resistant cell lines by miRNA microarray analysis. The two groups showed markedly different miRNA expression profiles, and 10 miRNAs were found to be regulated differentially between the two groups. When miR-141, which was the most highly expressed miRNA in the cisplatin-resistant cell lines, was expressed ectopically in the cisplatin-sensitive cell lines, cell viability after cisplatin treatment was increased significantly. Furthermore, we found that miR-141 directly targeted the 3¢-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents, and thus downregulated YAP1 expression. Our study highlights an important regulatory role for miR-141 in the development of cisplatin resistance in ESCC.

show abstract

“…18 Although upregulated in ovarian, bladder and breast carcinomas, [19][20][21] miR-205 has been reported to be downregulated in oesophageal cancers. 22 Thus, miR-205 might act as a doubled-edged sword by targeting opposite functional genes, as one miRNA can target a dozen mRNAs, impacting many molecules …”

Section: Mir-205 Suppresses Tumor Growth In Vivomentioning

confidence: 99%

miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth

Wang¹,

Li²,

Feng³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

The purpose of this study was to elucidate the molecular mechanisms of microRNA-205 (miR-205) as a tumor suppressor in prostate cancer (PCa). In the present study, microRNA microarray analysis suggested that the expression of miR-205 was significantly decreased in advanced PCa compared with early PCa. Real-time PCR analysis also indicated that miR-205 expression was significantly decreased in PCa tissues compared with non-cancerous tissues. Moreover, the expression of miR-205 has been demonstrated to be associated with the clinicopathological stage and total/free prostate-specific antigen (PSA) level of PCa. Functional analyses showed that both the overexpression of miR-205 and the knockdown of c-SRC in PCa cell lines could inhibit cell growth, colony formation, migration, invasion and the cell cycle as well as induce cell apoptosis in vitro. Furthermore, over-expressing miR-205 reduced tumorigenicity in vivo. Through a luciferase activity assay and Western blotting, c-SRC was identified as a target of miR-205 in cells. The overexpression of miR-205 suppressed c-SRC and its downstream signaling molecules, including FAK, p-FAK, ERK1/2 and p-ERK1/2, and attenuated cell proliferation, invasion and tumor growth.

show abstract

MicroRNA expression profiles of esophageal cancer

Abstract: Expression profiles of miRNA distinguish esophageal tumor histology and can discriminate normal tissue from tumor. MicroRNA expression may prove useful for identifying patients with Barrett esophagus at high risk for progression to adenocarcinoma.

Cited by 350 publications

References 38 publications

Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer

Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer

MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma

miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth

Contact Info

Product

Resources

About